Related Experiment Video
Updated: Oct 2, 2025
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
Published on: August 23, 2024
Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
Yuan Wang1,2, Jing He1,2, Manyu Xu3
1Department of Oncology, Affiliated Hospital of Nantong University, Nantong, China.
Abstract:
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase expressed at early stages of normal development and in various cancers including ALK-positive anaplastic large cell lymphoma (ALK+ ALCL), in which it is the main therapeutic target. ALK tyrosine kinase inhibitors (ALK TKIs) have greatly improved the prognosis of ALK+ALCL patients, but the emergence of drug resistance is inevitable and limits the applicability of these drugs. Although various mechanisms of resistance have been elucidated, the problem persists and there have been relatively few relevant clinical studies. This review describes research progress on ALK+ ALCL including the application and development of new therapies, especially in relation to drug resistance. We also propose potential treatment strategies based on current knowledge to inform the design of future clinical trials.
Insights
Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL) treatments show promise, but drug resistance remains a challenge. This review explores new therapies and strategies to overcome resistance in ALK+ ALCL.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Anaplastic lymphoma kinase (ALK) is a key target in ALK-positive anaplastic large cell lymphoma (ALK+ ALCL).
- ALK tyrosine kinase inhibitors (TKIs) have improved patient outcomes but face inevitable drug resistance.
- Mechanisms of resistance are known, yet clinical studies and effective strategies remain limited.
Purpose of the Study:
- To review research progress on ALK+ ALCL therapies.
- To focus on the development of new therapies addressing drug resistance.
- To propose future treatment strategies for ALK+ ALCL.
Main Methods:
- Literature review of ALK+ ALCL research.
- Analysis of current and emerging therapeutic approaches.
- Synthesis of information on drug resistance mechanisms.
Main Results:
- ALK TKIs are effective but resistance limits long-term efficacy.
- Various resistance mechanisms have been identified.
- New therapeutic strategies are under development to overcome resistance.
Conclusions:
- Overcoming drug resistance is crucial for improving ALK+ ALCL treatment.
- Further clinical studies are needed to validate novel therapeutic strategies.
- A combination of therapies may be required to manage resistance effectively.
